Claims for Patent: 7,582,301

Summary for Patent: 7,582,301

Title:	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
Abstract:	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
Inventor(s):	Bridon; Dominique P. (Outremont, CA), Dufresne; Robert P. (Wellseley, MA), Boudjellab; Nissab (Dorval, CA), Robitaille; Martin (Terrasse-Vaudreuil, CA), Milner; Peter G. (Los Altos Hills, CA)
Assignee:	Conjuchem Biotechnologies, Inc. (Montreal, Quebec, CA)
Application Number:	09/623,533
Patent Claims:	1. An antifusogenic peptide-albumin conjugate comprising: an anti-fusogenic peptide comprising a maleimide containing group and an amino acid sequence, wherein said sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, wherein said sequence exhibits an anti-viral and antifusogenic activity against human immunodeficiency virus (HIV) and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said peptide-albumin conjugate wherein the ratio of peptide to albumin in said conjugate is 1:1, and wherein said maleimide containing group is attached to said peptide without a linker or via a (2-amino)ethoxy acetic acid (AEA) or a [2-(2-amino) ethoxy] acetic acid (AEEA) linker. 2. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO:1. 3. An anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541. 4. A composition for use in the treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, an anti-fusogenic peptide-albumin conjugate comprising an anti-fusogenic peptide comprising a maleimide containing group and an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, wherein said sequence inhibits an anti-viral and anti-fusogenic activity against human immunodeficiency virus (HIV) and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said anti-viral peptide-albumin conjugate, wherein the ratio of peptide to albumin in said conjugate is 1:1, wherein said maleimide containing group is attached to said peptide without a linker or via a (2-amino)ethoxy acetic acid (AEA) or a [2-(2-amino) ethoxy] acetic acid (AEEA) linker. 5. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO:1. 6. The composition of claim 4, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541. 7. A composition comprising the anti-fusogenic peptide-albumin conjugate of claim 1 in a physiologically acceptable medium. 8. The composition of claim 7, wherein said amino acid sequence is SEQ ID NO:1. 9. The composition of claim 7, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:534; SEQ ID NO:535, SEQ ID NO:536; SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:539, SEQ ID NO:540, and SEQ ID NO: 541. 10. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said albumin is serum albumin. 11. The anti-fusogenic peptide-albumin conjugate of claim 10, wherein said albumin is human serum albumin. 12. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO:3. 13. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO:4. 14. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 5. 15. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 117. 16. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 118. 17. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 119. 18. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 534. 19. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 535. 20. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 536. 21. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 537. 22. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 538. 23. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 539. 24. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 540. 25. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 541. 26. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 3. 27. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 4. 28. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 5. 29. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 117. 30. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 118. 31. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 119. 32. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 534. 33. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 535. 34. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 536. 35. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 537. 36. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 538. 37. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 539. 38. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 540. 39. The composition of claim 4, wherein said amino acid sequence is SEQ ID NO: 541. 40. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein the maleimide containing group is maleimidopropionic acid (MPA) or gamma-maleimide-butyralamide (GMBA). 41. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein the maleimide containing group is attached to the peptide via the (2-amino)ethoxy acetic acid (AEA) or the [2-(2-amino) ethoxy] acetic acid (AEEA) linker. 42. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein the maleimide containing group is attached to the peptide without a linking group. 43. The composition of claim 4, wherein the maleimide containing group is maleimidopropionic acid (MPA) or gamma-maleimide-butyralamide (GMBA). 44. The composition of claim 4, wherein the maleimide containing group is attached to the peptide via the (2-amino)ethoxy acetic acid (AEA) or the [2-(2-amino) ethoxy] acetic acid (AEEA) linker. 45. The composition of claim 4, wherein the maleimide containing group is attached to the peptide without a linking group. 46. The anti-fusogenic peptide-albumin conjugate of claim 1, wherein the peptide exhibits anti-viral and anti-fusogenic activity by modulation of a viral-cellular fusion process involving a coiled-coil peptide structure. 47. The composition of claim 4, wherein the peptide exhibits anti-viral and anti-fusogenic activity by modulation of a viral-cellular fusion process involving a coiled-coil peptide structure.

Details for Patent 7,582,301

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2040-01-28